Soliqua 100/33 (insulin glargine/lixisenatide) is a brand-name injection pen that’s prescribed to improve blood sugar levels in adults with type 2 diabetes. The drug’s cost, with and without ...

The FDA has approved Novo Nordisk’s Xultophy and Sanofi’s Soliqua on the same day, pitching the rival diabetes combination into head-to-head competition. Both products combine a long acting ...

Soliqua is a once-daily injectable combination drug containing insulin, glargine 100 units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist. India Has The 2nd ...